Abstract:Background Metastasis in breast cancer is a vital concern in treatment because most women with primary breast cancer have micrometastases to distant sites at diagnosis. As a member of the inhibitor of apoptosis protein (IAP) family, survivin has been proposed as an attractive target for new anticancer interventions. In this study, we investigated the role of the plasmid encoding the phosphorylation-defective mouse survivin threonine 34→alanine mutant (Msurvivin T34A plasmid) in suppressing both murine primary breast carcinomas and pulmonary metastases. Methods In vitro study, induction of apoptosis by Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) was examined by PI staining fluorescence microscopy and flow cytometric analysis. The anti-tumor and anti-metastases activity of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) was evaluated in female BALB/c mice bearing 4T1 s.c. tumors. Mice were treated twice weekly with i.v. administration of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol), PORF-9 null plasmid complexed with cationic liposome (DOTAP/Chol), 0.9% NaCl solution for 4 weeks. Tumor volume was observed. After sacrificed, tumor net weight was measured and Lung metastatic nodules of each group were counted. Assessment of apoptotic cells by TUNEL assay was conducted in tumor tissue. Microvessel density within tumor tissue was determined by CD31 immunohistochemistry. Alginate-encapsulated tumor cells test was conducted to evaluate the effect on angiogenesis. By experiment of cytotoxicity T lymphocytes, we test whether Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) can induce specific cell immune response. Results Administration of Msurvivin T34A plasmid complexed with cationic liposome (DOTAP/Chol) resulted in significant inhibition in the growth and metastases of 4T1 tumor model. These anti-tumor and anti-metastases responses were associated with triggering the apoptosis of tumor cells directly, inhibiting angiogenesis and inducing specific cellular immune response. Conclusion The present findings suggest that the Msurvivin T34A plasmid complexed with cationic liposome may provide an effective approach to inhibit the growth and metastases of a highly metastatic mouse breast cancer model with minimal side effects.

Suppression Of Survivin Expression Inhibits In Vivo Tumorigenicity And Angiogenesis In Gastric Cancer

A Study on the Expression of Survivin Gene in Human Gastric Cancer

The expression of survivin in human gastric carcinoma and precancerous lesions.

Selection of Optimal Antisense Accessible Sites of Survivin and Its Application in Treatment of Gastric Cancer

Inhibition of survivin expression in BGC-823 cells by RNA interference

Inhibition of lymphatic metastases by a survivin dominant-negative mutant

Survivin Stable Knockdown by Sirna Inhibits Tumor Cell Growth and Angiogenesis in Breast and Cervical Cancers

Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant

[Inhibition Function of Dominant-negative Mutant Gene Survivin-D53A to SPC-A1 Lung Adenocarcinoma Xenograft in Nude Mice Models].

Effects of survivin gene siRNA on the growth of gastric cancer cell line

Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant

A Survivin Double Point Mutant Has Potent Inhibitory Effect on the Growth of Hepatocellular Cancer Cells

Expression of survivin and its Relationship with Apoptosis and Biological Behaviors of Gastric Cancer

Up‐regulation of Survivin by AKT and Hypoxia‐inducible Factor 1α Contributes to Cisplatin Resistance in Gastric Cancer

Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor

Targeted Inhibition Of Sp1-Mediated Transcription For Antiangiogenic Therapy Of Metastatic Human Gastric Cancer In Orthotopic Nude Mouse Models

Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues.

Effect of RNAi-Mediated Survivin and Hypoxia-Inducible Factor 1α Gene Silencing on Proliferation, Invasion, Migration and Apoptosis of Gastric Cancer BGC-823 Cells

Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model

[Inhibitory Effect Against the Gastric Carcinoma Cell Growth by the Combination of the Survivin Antisense Oligonucleotide and P53 Gene].

Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer